1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

 
• By Jo Shorthouse

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

world map country flags marked pin city pinpoint . mark the route for America
Companies Are Mapping Out New Ways To Treat CF Patients • Source: shutter stock

There is little doubt that Vertex Pharmaceuticals Inc.’s cystic fibrosis transmembrane conductance regulator (CFTR) modulators Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) have changed the face of treatment for cystic fibrosis patients. With the approval of Symdeko (tezacaftor), the base therapy for a triple combination with next-generation CFTR modulators, Vertex’s rule of what is forecast to be an $8.6bn market by 2025 is clear for the foreseeable future.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.